EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ten year review of survival of patients with advanced non-seminomatous germ cell tumours The Weston Park experience



Ten year review of survival of patients with advanced non-seminomatous germ cell tumours The Weston Park experience



British Journal of Cancer 83(Supplement 1): 78, July




(PDF emailed within 1 workday: $29.90)

Accession: 035835042

Download citation: RISBibTeXText



Related references

Retroperitoneal lymph node dissection in clinical stage I non-seminomatous germ cell testicular tumours Long term results in a single-center 16-year experience. European Urology Supplements 1(1): 94, January, 2002

Advanced male non-seminomatous germ-cell tumours. Combination chemotherapy with cis-platinum, vinblastine and bleomycin. Medical Journal of Australia 2(12): 630-632, 1979

Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours. Lancet 1(8419): 8-11, 1985

Resection of residual masses after chemotherapy for advanced non-seminomatous germ cell tumours, a monocentric analysis of pre-operative prognosticators. European Journal of Cancer Care 19(6): 827-832, 2011

Localised gonadal non-seminomatous germ cell tumours French Society of Pediatric Oncology Experience. Jones, W G , Harnden, P , Appleyard, I Advances in the Biosciences; Germ cell tumours III 437, 1994

Experience of discordant beta hCG results by different assays in the management of non-seminomatous germ cell tumours of the testis. Clinical Oncology ) 11(6): 388-392, 2000

Prognostic factors in non-seminomatous germ cell tumours of the testis. Experience at the Institut Gustave-Roussy. European Urology 23(1): 188-195, 1993

Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. British Journal of Cancer 74(8): 1280-1285, 1996

Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. Thoracic Cancer 6(4): 399-406, 2015

Retroperitoneal lymphadenectomy following chemotherapy in advanced non-seminomatous germ cell tumours: I. Intraoperative findings in tumors after seroconversion of tumour markers. Urologe Ausgabe A 32(3): 189-193, 1993

Four drug combination chemotherapy consisting of etoposide, cisplatin, bleomycin and cyclophosphamide for advanced metastatic non-seminomatous germ cell tumours. Jones, W G, Harnden, P, Appleyard, I Advances in the Biosciences; Germ cell tumours III 421-422, 1994

Long-term results of operative therapy for metastasized non-seminomatous germ cell tumours (NSGT) in advanced tumour stages. Urologe Ausgabe A 36(4): 339-342, 1997

Prognostic factors in metastatic non-seminomatous germ cell tumours: an interim analysis of the EORTC GU-Group experience. European Urology 23(1): 202-206, 1993